Teleflex Debuts Dynetic-35 Stent System at CIRSE 2026, Highlighting Trans-Radial Access Success — Teleflex Incorporated

Event summary

Teleflex showcased the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 in Copenhagen.
The system demonstrated a 100% procedural success rate via trans-radial access in the BIONETIC-TRA study.
The study, led by Dr. Michael Lichtenberg, addressed challenges of traditional femoral artery access in iliac artery interventions.
The Dynetic™-35 Stent System features a cobalt chromium alloy with proBIO™ Coating and compatibility with 6F delivery systems.

The big picture

Teleflex's introduction of the Dynetic-35 Stent System at CIRSE 2026 underscores the growing trend towards minimally invasive, trans-radial access in vascular interventions. The successful outcomes from the BIONETIC-TRA study position Teleflex to compete in the peripheral stent market, particularly for patients with complex access challenges. The strategic focus on low-profile catheter-based technologies aligns with broader industry shifts towards less invasive procedural options.

What we're watching

Clinical Adoption: How the trans-radial approach with the Dynetic-35 Stent System will affect adoption rates in iliac artery interventions.
Regulatory Approval: Whether the Dynetic-35 Stent System can secure regulatory approval in the United States and other key markets.
Market Differentiation: The pace at which Teleflex can differentiate its product in a competitive peripheral stent market.